In the latest developments, the University of California/Berkeley, the University of Vienna, and Emmanuelle Charpentier (collectively known as “CVC”) have filed their response and reply brief on May 19th in the face of an ongoing consideration by the Patent Trial and Appeal Board (PTAB). This action comes as an appeal against an unfavorable decision on priority in Interference No. 106,115, particularly focusing on CRISPR-mediated gene editing. The original briefing was presented by the Broad Institute, Harvard University, and MIT, who are collectively referred to as “Broad”.
The heart of the dispute involves the contention on precedence of the invention and application of CRISPR-mediated gene editing technology, a revolutionary technique in genome engineering. The contention led to legal intervention, culminating in Interference No. 106,115. The unfavorable conclusion arrived by the PTAB spurred the recent appeal and response by “CVC”.
This legal battle is increasingly shaping the landscape of patent rights in gene editing technology, with both sides asserting their stances with unyielding resolution. The filing by “CVC” constitutes a critical development in this ongoing legal tussle.
The details of the filing and Interference No. 106,115 can be further explored at
JD Supra.